These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24640306)

  • 1. [Dermocosmetology as a support for targeted oncologic treatment].
    Piérard-Franchimont C; Lesuisse M; Piérard GE
    Rev Med Liege; 2014 Jan; 69(1):35-7. PubMed ID: 24640306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.
    Dreno B; Bensadoun RJ; Humbert P; Krutmann J; Luger T; Triller R; Rougier A; Seité S
    J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1071-80. PubMed ID: 23368717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Skin damage by extravasation of chemotherapeutic agents].
    Yamamoto A
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():464-9. PubMed ID: 25831804
    [No Abstract]   [Full Text] [Related]  

  • 4. Skin care for cancer patients.
    Lacouture ME
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management.
    Varvaresou A; Iakovou K; Mellou F; Myrogiannis D; Papageorgiou S
    J Cosmet Dermatol; 2020 Apr; 19(4):782-788. PubMed ID: 31769600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.
    Choi JN
    Clin Dermatol; 2011; 29(6):587-601. PubMed ID: 22014981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
    Balagula Y; Garbe C; Myskowski PL; Hauschild A; Rapoport BL; Boers-Doets CB; Lacouture ME
    Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Skin disorders].
    Uhara H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():450-3. PubMed ID: 25831801
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.
    Cury-Martins J; Eris APM; Abdalla CMZ; Silva GB; Moura VPT; Sanches JA
    An Bras Dermatol; 2020; 95(2):221-237. PubMed ID: 32165025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dermatological reactions in patients in antineoplastic therapy].
    Prasad SC; Vestergaard H; Bygum A
    Ugeskr Laeger; 2014 May; 176(11):. PubMed ID: 25096844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Managing cutaneous toxicities of targeted therapies].
    Kiyohara Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preventing dermatopathy of patients receiving cancer chemotherapy].
    Sasaki Y; Higuchi M; Matsuo K; Wada Y; Iwatsubo S; Nishino H
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1741-5. PubMed ID: 20841938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative disorder therapy: assessment and management of adverse events--a dermatologist's perspective.
    Soutou B; Aractingi S
    Hematol Oncol; 2009 Jun; 27 Suppl 1():11-3. PubMed ID: 19468982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dermatologic toxicities.
    Lacouture ME
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):686-9. PubMed ID: 25995431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatologic toxicity of chemotherapeutic agents.
    Payne AS; James WD; Weiss RB
    Semin Oncol; 2006 Feb; 33(1):86-97. PubMed ID: 16473647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Skin toxicity].
    Sato A; Hamada K; Imataka H
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1767-72. PubMed ID: 22083182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
    Viale PH
    Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Managing nausea and vomiting in thoracic oncology].
    Le Moulec S; Vedrine L
    Rev Pneumol Clin; 2008 Apr; 64(2):76-80. PubMed ID: 18589287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.